Bausch + Lomb Acquires Trukera Medical

Alcon to Acquire LumiThera

July 7, 2025

Medical Devices

Alcon, a leader in eye care, plans to acquire LumiThera, which develops light-based therapies for ophthalmology, including its photobiomodulation (PBM) device for treating early and intermediate dry age-related macular degeneration (AMD). The acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions and a LumiThera shareholder vote.

Bausch + Lomb Affiliate Acquires Whitecap Biosciences

January 13, 2025

Pharmaceuticals

An affiliate of Bausch + Lomb Corporation has acquired clinical-stage Whitecap Biosciences, LLC, which is developing two ophthalmic therapies (WB007 and WB006) for glaucoma and geographic atrophy. The deal strengthens Bausch + Lomb's clinical-stage pipeline — Whitecap completed a Phase 2 study for WB007 and plans additional trials for both indications.

Bausch + Lomb Acquires Elios Vision

December 11, 2024

Medical Devices

Bausch + Lomb Corporation (through an affiliate) has acquired Elios Vision, Inc., developer of the ELIOS excimer-laser MIGS system, expanding Bausch + Lomb's glaucoma surgical capabilities and complementing its cataract surgery portfolio. The ELIOS technology, currently CE marked and marketed in the EU, is undergoing pursuit of FDA approval and will be commercialized more broadly through Bausch + Lomb's global cataract surgery channels.

Bausch + Lomb Acquires AcuFocus, Inc.

January 17, 2023

Medical Devices

Bausch + Lomb Corporation has acquired AcuFocus, Inc. through an affiliate via a merger with AcuFocus’s parent company. The acquisition adds AcuFocus’s IC‑8 Apthera small‑aperture extended‑depth‑of‑focus intraocular lens to Bausch + Lomb’s surgical portfolio to expand capabilities in premium cataract IOL offerings.

SpendMend Acquires Trulla, Pharmacy Procurement Software Pioneer

August 16, 2022

Healthcare Services

SpendMend, in partnership with Morgan Stanley Capital Partners, has acquired Trulla, a Draper, Utah-based provider of pharmacy procurement software and analytics. The deal integrates Trulla's procurement, pricing-algorithm and analytics capabilities into SpendMend's pharmacy suite to help health systems, hospitals, and clinics reduce pharmacy costs and manage 340B program compliance.

Accelmed Partners II Acquires TearLab Corporation

July 9, 2020

Medical Devices

Accelmed Partners II (AP-II) has completed a buyout of TearLab Corporation, a developer of point-of-care tear diagnostic devices, positioning the company as a private entity to pursue development of its next-generation Discovery platform and targeted acquisitions. The transaction includes a planned investment to support growth, pay down debt, and build a comprehensive dry eye care platform for eyecare professionals and patients.